Nasal Congestion

Nasal congestion and Rhinorrhea
Ali Sepehr
Rhinosinusitis.ppt

Treatment of Allergic Rhinitis
Priya Vasudevan
Treatment of Allergic Rhinitis.ppt

Acute and Chronic Sinusitis
A Practical Guide for Diagnosis and Treatment
Sinusitis.ppt

Pediatric Rhinosinusitis
Sarah Rodriguez, MD, Matthew Ryan, MD
Pedi-sinus-slides.ppt

Turbinate Dysfunction
Shashidhar S. Reddy, MD, MPH, Matthew Ryan, MD
Turbinate Dysfunction.ppt

Medical Management of Allergic Rhinitis
Camysha Wright, Jing Shen
Medical Management of Allergic Rhinitis.ppt

Antihistamines, Decongestants, Antitussives, and Expectorants
Resp_Antihistamines.ppt

Interferences with Ventilation
Interferences with Ventilation.ppt

Difficulty breathing
Difficulty breathing.ppt

Drugs Affecting Respiratory System
Jan Bazner-Chandler MSN, CNS, RN, CPNP
Drugs Affecting Respiratory System.ppt

Drugs for Allergic Rhinitis, Cough, and Colds
Drugs for Allergic Rhinitis, Cough, and Colds.ppt

Allergic Rhinitis in Children
Dr. KANUPRIYA CHATURVEDI
Allergic Rhinitis in Children.ppt

Probiotics and Allergy
Shalini Jain , Hariom Yadav and PR Sinha
Probiotics and Allergy.ppt

MICROBIOLOGY OF OTITIS, SINUSITIS, AND MENINGITIS
PAUL A. GULIG, PH.D.
ot-sin-men-11.ppt

Seasonal Allergies: Antihistamines & the Future
Jacquelyn Covarrubias
AntihistaminesJC.ppt

Diseases of the Respiratory System
Diseases of the Respiratory System.ppt

Squamous papillomas of the nasal
Squamous papillomas of the nasal.ppt

Drugs for Common Upper Respiratory Infections
Drugs for Common Upper Respiratory Infections.ppt

Leukotriene Inhibitors: Uses Beyond Asthma
Duane L. Keitel
http://intmedweb.wfubmc.edu/download/leukotriene.ppt

Respiratory Drugs
Nancy Pares, RN, MSN
Respiratory Drugs.ppt

Otalgia
Otalgia.ppt

Swine Influenza
Jassma Taylor
Swine.ppt

Management of patients with upper respiratory tract disorder
Mrs. Mahdia Samaha Alkony
Management of patients.ppt

Allergic Rhinitis
Maianh Phung
Allergic Rhinitis.ppt

Understanding Influenza: A Contagious Respiratory Illness
Influenza.ppt
126 Published articles

Read more...

Pioglitazone anti-diabetic drug cause 40% rise in the risk of bladder cancer

Doctors say go slow on use of diabetes drug after study sees cancer risk
Published in Times of India Dt. 3rd June, 2012

Chennai: Doctors in India are seeking restraint in the use of commonly used anti-diabetic drug pioglitazone after studies showed that it increases the risk of bladder cancer. Diabetologists in India say they are already seeing bladder cancers even among those who have been on lower dosages of the drug for two years or more.

    Piolglitazone, sold under many brand names such as Glizone and Pioz in India, is a prescription drug of the thiazolidinedione class that is used to bring down sugar levels in diabetics. Another medication in the same class, rosiglitazone, was withdrawn from the market in 2010 following studies showed increased risk of cardiovascular diseases.

    Now, a study published in the British Medical Journal has said exposure to pioglitazone for two years may more than double the risk of developing bladder cancer. The bladder cancer risk among patients taking the drug increases by about 83% compared to the rest of the population, the researchers said.

    Of the 115,727 patients in the UK who were part of the study, 470 of them were found to have bladder cancer. This would mean that one in every 250 patients taking the drug for more than two years is at increased risk for cancer.

    There has been no detailed study on the effectiveness of the drug in India. US agency found drug increased risk of cancer
    Some doctors say they are beginning to see new bladder cancer cases in people who have been taking lower doses (15mg) of the drug for two years.

    As a part of an ongoing study, Madras Diabetes Research Foundation has collected medical details of eight patients who developed bladder cancer after being prescribed pioglitazone. The patients were from Mumbai, Hyderabad, Chennai, Belgaum and Salem. “None of them had bladder cancer before they were prescribed the drug. It is possiblethateven lower dosages increase the risk in Indians,” said foundation director Dr V Mohan.

    The US Food and Drug Administration warned in June 2011 that taking pioglitazone for at least a year increased the risk of bladder cancer by at least 40%, and ordered the drug’s manufacturer to note the risk on the drug’s label. The drug is banned in some countries like France and Germany. Dr Mohan insists that the drug should be banned for new patients and those who have been on the drug should be warned about the risks.

    But some diabetologists argue that the benefits outweigh risks andthedrug has notbeen shown as the cause of bladder cancer, and the researchers themselves say that the risk applies to people who have been taking the maximum dosage -- 45mg every day -- for two years. They also add that it should be continued as no risk has been proved for those taking 15mg and 30mg. “Itisoneof the most effective drugs to bring sugar levels under control. Without this drug, the only option for the patientisinsulin,” said a senior diabetologist, refusing to be named.

    India has 61 million diabetics – a sizeable increase from 50.8 million in 2010. The International Diabetes Federation estimates that by 2030, India’s diabetes burden is expected to cross the 100 million mark as against 87 million estimated earlier.

http://www.bmj.com/rapid-response/2011/11/03/ema-bis-repetita
http://www.bmj.com/search/pioglitazone

Read more...

Dyslipidemia

Dyslipidemia: High blood cholesterol levels.
Lipid disorders; Hyperlipoproteinemia; Hyperlipidemia; Dyslipidemia; Hypercholesterolemia

Dyslipidemia
Dyslipidemia .ppt

Diabetes Is a CHD Risk Equivalent
Diabetes Is a CHD Risk Equivalent.ppt

New Concepts in the Evaluation and Treatment of Dyslipidemia
Nathan D. Wong, PhD, FACC
New Concepts in the Evaluation and Treatment of Dyslipidemia.ppt
Epidemiology Clinical Trials Mgm.ppt

Approaches To Dyslipidemia Treatment in Children and Adolescents
Lorenzo Iughetti; Barbara Predieri; Patrizia Bruzzi; Fiorella Balli
Dyslipidemia_Treatment_Children_Adolescents2011.ppt

Hypertriglyceridemia
Jenny Gordon
Tryglycerides.ppt

Diabetes Mellitus and Hypertension: Diagnosis and Management
T. Villela, M.D.
Diabetes.ppt

Awareness, Treatment and Control of Hypertension among Filipino Americans
Mariano Rey, M.D.
Awareness_Tx_Control_HTN.ppt

Treatment of Dyslipidemia
Treatment of Dyslipidemia.ppt

Lipid droplet proteins in the control of cellular lipid metabolism
Perry Bickel
Lipid droplet proteins in the control of cellular lipid metabolism.ppt

Interactive Case Presentation
Doug Kutz MD
Interactive Case Presentation.ppt

Hypertension: New Trials – Best Treatments
Karen Moncher, MD
Hypertension: New Trials – Best Treatments.ppt

CHD is the single largest killer
CHD is the single largest killer.ppt

Hyperlipidemia
Hyperlipidemia.ppt

Linked Metabolic Abnormalities
http://www.pitt.edu/~super4/33011-34001/33711.ppt

Cardiometabolic Syndrome
Nabil Sulaiman
http://www.pitt.edu/~super4/33011-34001/33751.ppt
http://www.pitt.edu/~super7/5011-6001/5311.ppt

Atherosclerotic Vascular Disease Risk Factors, Screening to Prevent
David R. Rudy, M.D., M.P.H.
Atherosclerotic Vascular Disease Risk Factors, Screening to Prevent.ppt

Diabetes Guidelines and Treatment
Diabetes Guidelines and Treatment.ppt

Primary Biliary Cirrhosis (PBC)
Thomas W. Faust, M.D., M.B.E.
Primary Biliary Cirrhosis.ppt

Diabetes: Guideline-Based Management
Eric L. Johnson, M.D.
DiabetesGuidelinemanagement5-12-11.ppt

Dyslipidemia
Stanford Massie M.D.
Hyperlipidemia.ppt

The Relationship of Weight and Obstructive Sleep Apnea
Mia Zaharna, MD, MPH
The Relationship of Weight and Obstructive Sleep Apnea.ppt
536 free full text articles

Read more...